格隆汇8月22日丨九典制药(300705.SZ)公布2025年半年度报告，上半年公司实现营业收入15.12亿元，同 步在10.67%；归属于上市公司股东的净利润2.91亿元，同比增长2.57%；归属于上市公司股东的扣除非 经常性损益的净利润2.83亿元，同比增长10.74%；基本每股收益0.59元。 ...

2025 年半年度跟踪报告 | 保荐人名称：西部证券股份有限公司 | 被保荐公司简称：九典制药 | | --- | --- | | 保荐代表人姓名：江伟 | 联系电话：0731-84727299 | | 保荐代表人姓名：徐飞 | 联系电话：0731-84727299 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0次 | | 2、督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限于防 | | | 止关联方占用公司资源的制度、募集资金管理制度、内控 | 是 | | 制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 2次 | | （2）公司募集资金项目进展是否与信息披露文件一致 | 是 | | 4、公司治理督导情况 | | | （1）列席公司股东会次数 | 1次 | | （2）列 ...

西部证券股份有限公司关于 湖南九典制药股份有限公司改变募集资金用途的核查意见 西部证券股份有限公司（以下简称"西部证券"或"保荐人"）作为湖南九 典制药股份有限公司（以下简称"九典制药"、"上市公司"或"公司"）向不特 定对象发行可转换公司债券持续督导的保荐人，根据《证券发行上市保荐业务管 理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》《上市公司募集资金监管规则》 等相关法律法规、规范性文件要求，对九典制药改变募集资金用途的情况进行了 审慎核查，具体核查情况如下： 一、募集资金基本情况 （一）募集资金基本情况 经中国证券监督管理委员会出具的《关于同意湖南九典制药股份有限公司向 不特定对象发行可转换公司债券注册的批复》（证监许可[2021]62 号）的核准， 公司向不特定对象发行不超过人民币 270,000,000.00 元的可转换公司债券。本次 向不特定对象发行可转换公司债券，每张面值为人民币 100 元，发行数量 2,700,000.00 张，发行价格为人民币 100 元/张，募集资金总额为人民币 270,000,000.00 元，扣 ...

Financial Performance - The company's operating revenue for the reporting period was CNY 1,511,949,503.84, representing a 10.67% increase compared to CNY 1,366,190,189.06 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was CNY 291,423,208.95, a 2.57% increase from CNY 284,130,488.69 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was CNY 282,781,130.52, reflecting a 10.74% increase from CNY 255,356,726.55 year-on-year[18]. - The net cash flow from operating activities decreased by 33.99% to CNY 275,892,863.89, down from CNY 417,957,180.05 in the previous year[18]. - Total assets at the end of the reporting period were CNY 3,531,462,911.24, an increase of 4.69% from CNY 3,373,131,232.71 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company were CNY 2,589,926,055.79, up 2.50% from CNY 2,526,729,860.86 at the end of the previous year[18]. - The basic earnings per share remained unchanged at CNY 0.59, while diluted earnings per share decreased by 1.69% to CNY 0.58[18]. - The weighted average return on net assets was 11.12%, down from 13.51% in the previous year, a decrease of 2.39%[18]. Market Position and Product Development - The company holds a leading market position with 100% market share for its main products, including Loxoprofen Sodium Gel and Ketoprofen Gel, in both 2023 and 2024[28]. - The company has a total of 90 registered raw material drug varieties, with 74 in A status, indicating a strong production capability in the pharmaceutical sector[30]. - The company is recognized as a major GMP producer of Oseltamivir Phosphate and has established a strong market presence in over 60 countries and regions, including the US and Europe[30]. - The company’s main products, such as Pantoprazole Sodium Enteric-coated Tablets, maintained a market share of 31.47% in 2023, projected to increase to 32.21% in 2024[28]. - The company is focusing on high-end excipients, particularly for biological vaccines, achieving domestic leadership and international advanced quality standards[30]. - The company is committed to expanding its product range and enhancing its research and development capabilities to meet the evolving healthcare demands[27]. - Key products include Loxoprofen Sodium Gel for pain relief and Pantoprazole Sodium Enteric-coated Tablets for digestive issues, indicating a diverse product portfolio[33]. - The company is actively involved in the development of pharmaceutical excipients, with applications in injections and oral solid formulations, enhancing its manufacturing capabilities[35]. Research and Development - The company has a strong R&D team of over 400 members, focusing on transdermal drug delivery systems and has established multiple innovative platforms[48]. - R&D investment has consistently accounted for over 10% of revenue for several years, with a research team of over 100 members and laboratory space exceeding 2,000 square meters[52]. - The company is focusing on research and development of new technologies to improve drug efficacy and patient outcomes, reflecting its innovation strategy[33]. - The company has successfully developed and industrialized key technologies in transdermal drug delivery, creating significant competitive advantages[48]. - The company has registered a total of 576 trademarks, with 104 new trademarks added during the reporting period[53]. Compliance and Risk Management - The company has acknowledged potential risks in its management and operations, which are detailed in the report[3]. - The company is enhancing its compliance framework to mitigate commercial bribery risks, ensuring ethical business practices[32]. - The company is actively managing risks related to intellectual property protection to maintain competitive advantages and prevent potential disputes[96]. - The company is committed to effective cost control and market expansion to mitigate the impact of increased environmental protection expenditures on profitability[100]. Environmental and Social Responsibility - The company has implemented advanced wastewater and waste gas treatment processes, achieving a wastewater treatment capacity of 1,200 tons per day[68]. - The company received multiple environmental honors, including the "National Green Factory" award in 2019 and the "Changsha Demonstration Water Carrier" title in 2021[118]. - In the first half of 2025, the company donated 20,000 yuan to the Liaoning Red Cross Foundation to support chronic disease treatment initiatives[120]. - The company has established a comprehensive recycling system, including waste heat recovery and solvent recycling, to minimize environmental impact and reduce production costs[118]. Shareholder and Governance - The company emphasizes the protection of shareholder rights and has optimized its governance structure to ensure transparency[114]. - The company has not implemented an employee stock ownership plan or other employee incentive measures[111]. - The company has approved a share repurchase plan with a total fund of no less than RMB 100 million and no more than RMB 150 million, with a maximum repurchase price of RMB 24.98 per share[151]. - Major shareholder Zhu Zhihong holds 33.12% of the shares, with a total of 41,415,900 shares pledged[156]. - The company has a total of 38,753 shareholders at the end of the reporting period[156]. Financial Management and Investments - The company has committed to invest in new drug research and development, with a total investment amount of 10.8 million yuan[85]. - The company has received multiple international certifications, including 10 certifications from the EU and 16 site audits from international clients[63]. - The company has engaged with various investment institutions to discuss operational performance, research developments, and strategic planning[102]. - The company has reported a total of 11.06 million in pre-invested costs for fundraising projects[86].

Group 1 - The company reported a revenue of 1.512 billion yuan for the first half of 2025, representing a year-on-year growth of 10.67% [1] - The net profit for the same period was 291 million yuan, showing a year-on-year increase of 2.57% [1]

湖南九典制药股份有限公司 章 程 二〇二五年八月 1 | | | | 第一章 | 总则 | 3 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 4 | | 第三章 | 股份 | 4 | | 第四章 | 股东和股东会 | 8 | | 第五章 | 董事会 | 24 | | 第六章 | 总经理及其他高级管理人员 32 | | | 第七章 | 监事会 | 34 | | 第八章 | 财务会计制度、利润分配和审计 37 | | | 第九章 | | 41 | | | 通知和公告 | | | 第十章 | 合并、分立、增资、减资、解散和清算 42 | | | 第十一章 | 修改章程 | 45 | | 第十二章 | 附则 | 46 | 第一章 总则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）和其他有关规定，制订本章程。 第二条 湖南九典制药股份有限公司系依照《公司法》和其他有关规定成立 的股份有限公司（以下简称"公司"）。 公司系在湖南九典制药有限公司的基础上，依法 ...

| 证券代码：300705 | 证券简称：九典制药 | | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | 公告编号：2025-060 | 湖南九典制药股份有限公司 关于 2025 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）根据《上市公司监管指引 第 2 号—上市公司募集资金管理和使用的监管要求》和《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》的规定，将 2025 年半年 度募集资金存放与使用情况专项报告如下： 一、募集资金基本情况 1、实际募集资金金额、资金到账时间 经中国证券监督管理委员会出具的《关于同意湖南九典制药股份有限公司向 不特定对象发行可转换公司债券注册的批复》（证监许可[2021]62 号）同意注册， 公司向不特定对象发行不超过人民币 270,000,000.00 元的可转换公司债券。本 次向不特定对象发行可转换公司债券，每张面值为人民币 100 元，发行数量 2,700,0 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-061 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转 02 | | 湖南九典制药股份有限公司 关于改变募集资金用途的公告 本公司及董事会全体成员保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司""九典制药"）于 2025 年 8 月 21 日召开第四届董事会第十二次会议和第四届监事会第八次会议，审议通 过了《关于改变募集资金用途的议案》，同意公司结合政策和市场环境变化、整 体经营布局调整等实际情况，改变向不特定对象发行可转换公司债券募集资金用 途。本议案不涉及关联交易，尚需提交股东会审议。现将有关事项公告如下： 经中国证券监督管理委员会出具的《关于同意湖南九典制药股份有限公司向 不特定对象发行可转换公司债券注册的批复》（证监许可[2021]62 号）的核准， 公司向不特定对象发行不超过人民币 270,000,000.00 元的可转换公司债券。本 次向不特定对象发行可转换公司债券，每张面值为人民币 100 元，发行 ...

| 编制单位：湖南九典制药股份有限公司 | | | | | | | | | | 金额单位：人民币万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占 | 资金占用方名称 | 占用方与上市公 | 上市公司核算的 | 2025年初占用资 | 2025年1-6月占用累计发 | 2025年1-6月占用资 | 2025年1-6月偿 | 2025年6月末占 | 占用形成原因 | 占用性质 | | 用 | | 司的关联关系 | 会计科目 | 金余额 | 生金额（不含利息） | 金的利息（如有） | 还累计发生额 | 用资金余额 | | | | 控股股东、实际 控制人及其附属 | | | | | | | | | | 非经营性占用 | | 企业 | | | | | | | | | | 非经营性占用 | | 小 计 | —— | —— | —— | | | | | | —— | —— | | 前控股股东、实 际控制人及其附 | | | | | | | | | | 非经营性占用 | | 属企业 | | | | | | | ...

Core Insights - The company announced the acquisition of all developed results and corresponding intellectual property of JIJ02 gel from Chengdu Ped Bio-pharmaceutical Co., Ltd. for 90 million yuan [1] - The company has completed the transfer procedures for the clinical approval documents related to the product [1] Group 1 - The acquisition amount for the JIJ02 gel is 90 million yuan [1] - The original name of the gel was "PD-DP-008 gel" [1] - The company signed a technology transfer contract with Chengdu Ped [1]